[S02DA03, antipyrine, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Antipyrine.]
[B01AD01, streptokinase, The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefotaxime.]
[J01GA01, streptomycin, Cefotaxime may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[A02BX02, sucralfate, Cefotaxime may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Cefotaxime may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Cefotaxime may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, Cefotaxime may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M01AB02, sulindac, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Sulindac.]
[N03AX03, sulthiame, The therapeutic efficacy of Sulthiame can be decreased when used in combination with Cefotaxime.]
[M01AX04, apazone, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Azapropazone.]
[L01BB02, mercaptopurine, The excretion of Mercaptopurine can be decreased when combined with Cefotaxime.]
[N05CD07, temazepam, Cefotaxime may decrease the excretion rate of Temazepam which could result in a higher serum level.]
[R03CC03, terbutaline, Cefotaxime may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Cefotaxime may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Cefotaxime may decrease the excretion rate of Testosterone which could result in a higher serum level.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Tetracaine.]
[S03AA02, tetracycline, The excretion of Tetracycline can be decreased when combined with Cefotaxime.]
[J01DI02, ceftaroline fosamil, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Ceftaroline fosamil.]
[P02CA02, thiabendazole, Cefotaxime may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[R06AD03, thiethylperazine, Cefotaxime may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.]
[N05CA19, thiopental, The therapeutic efficacy of Thiopental can be decreased when used in combination with Cefotaxime.]
[G04BE06, moxisylyte, Cefotaxime may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Cefotaxime may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, Cefotaxime may decrease the excretion rate of Ticlopidine which could result in a higher serum level.]
[S01ED01, timolol, Cefotaxime may decrease the excretion rate of Timolol which could result in a higher serum level.]
[P01AB02, tinidazole, Cefotaxime may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Cefotaxime may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Cefotaxime may decrease the excretion rate of Tolazamide which could result in a higher serum level.]
[V04CA01, tolbutamide, Cefotaxime may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Tolmetin.]
[N02AX02, tramadol, Cefotaxime may decrease the excretion rate of Tramadol which could result in a higher serum level.]
[C03DB02, triamterene, The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Cefotaxime.]
[N05CD05, triazolam, Cefotaxime may decrease the excretion rate of Triazolam which could result in a higher serum level.]
[A16AX12, trientine, Cefotaxime may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, The excretion of Trifluridine can be decreased when combined with Cefotaxime.]
[A03AA05, trimebutine, Cefotaxime may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N03AC02, trimethadione, The therapeutic efficacy of Trimethadione can be decreased when used in combination with Cefotaxime.]
[J01EA01, trimethoprim, Cefotaxime may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[R03DX07, roflumilast, Cefotaxime may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Cefotaxime may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[R02AA14, oxyquinoline, Cefotaxime may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[B01AD04, urokinase, The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefotaxime.]
[S01AA28, vancomycin, Cefotaxime may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The therapeutic efficacy of Ezogabine can be decreased when used in combination with Cefotaxime.]
[B01AF01, rivaroxaban, Cefotaxime may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[B01AC24, ticagrelor, The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefotaxime.]
[C08DA01, verapamil, Cefotaxime may decrease the excretion rate of Verapamil which could result in a higher serum level.]
[N06AX09, viloxazine, Cefotaxime may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[B03BA01, vitamin B12, Cefotaxime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.]
[B01AA03, warfarin, Cefotaxime may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[J05AF01, zidovudine, The excretion of Zidovudine can be decreased when combined with Cefotaxime.]
[N03AX14, levetiracetam, The therapeutic efficacy of Levetiracetam can be decreased when used in combination with Cefotaxime.]
[M05BA03, pamidronic acid, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefotaxime.]
[M05BA05, tiludronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotaxime is combined with Tiludronic acid.]
[B06AC02, icatibant, Cefotaxime may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[B01AE01, desirudin, The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotaxime.]
[A02BC04, rabeprazole, Cefotaxime may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotaxime is combined with Ibandronate.]
[V03AC02, deferiprone, Cefotaxime may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, Cefotaxime may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, Cefotaxime may decrease the excretion rate of Tolterodine which could result in a higher serum level.]
[J01DH04, doripenem, The excretion of Doripenem can be decreased when combined with Cefotaxime.]
[M01CB03, auranofin, Cefotaxime may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[B03XA04, peginesatide, Cefotaxime may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Cefotaxime may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Cefotaxime may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Cefotaxime may decrease the excretion rate of Gemcitabine which could result in a higher serum level.]
[J01CA09, azlocillin, The risk or severity of seizure and encephalopathy can be increased when Cefotaxime is combined with Azlocillin.]
[J01DF01, aztreonam, Cefotaxime may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Bacitracin.]
[M03BX01, baclofen, Cefotaxime may decrease the excretion rate of Baclofen which could result in a higher serum level.]
[A08AA11, lorcaserin, Cefotaxime may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, Cefotaxime may decrease the excretion rate of Mirabegron which could result in a higher serum level.]
[L02BB04, enzalutamide, Cefotaxime may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[B01AX01, defibrotide, The therapeutic efficacy of Defibrotide can be decreased when used in combination with Cefotaxime.]
[N05CA04, barbital, The therapeutic efficacy of Barbital can be decreased when used in combination with Cefotaxime.]
[D02BA02, octinoxate, Cefotaxime may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[N04BD02, rasagiline, Cefotaxime may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N03AX22, perampanel, The therapeutic efficacy of Perampanel can be decreased when used in combination with Cefotaxime.]
[V09IX04, fluorodeoxyglucose F18, Cefotaxime may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[V08CA11, gadofosveset, Cefotaxime may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[B01AF02, apixaban, The therapeutic efficacy of Apixaban can be decreased when used in combination with Cefotaxime.]
[A16AX08, teduglutide, Cefotaxime may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[A10BH04, alogliptin, Cefotaxime may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Cefotaxime may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[L04AX06, pomalidomide, Cefotaxime may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02BA10, benorilate, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Benorilate.]
[A10BK02, canagliflozin, Cefotaxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Benzocaine.]
[L03AA12, ancestim, Cefotaxime may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Cefotaxime.]
[N04AC01, benztropine, Cefotaxime may decrease the excretion rate of Benzatropine which could result in a higher serum level.]
[R02AX03, benzydamine, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Benzydamine.]
[L01EE01, trametinib, Cefotaxime may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Cefotaxime may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, Cefotaxime may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[A10BJ03, lixisenatide, Cefotaxime may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[A05AA03, cholic acid, The excretion of Cholic Acid can be decreased when combined with Cefotaxime.]
[C02KX04, macitentan, Cefotaxime may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[N06AX26, vortioxetine, Cefotaxime may decrease the excretion rate of Vortioxetine which could result in a higher serum level.]
[G03AC08, etonogestrel, Cefotaxime may decrease the excretion rate of Etonogestrel which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Cefotaxime.]
[J05AP08, sofosbuvir, Cefotaxime may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Cefotaxime.]
[C01CA27, droxidopa, Cefotaxime may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[N05CH03, tasimelteon, Cefotaxime may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, Cefotaxime may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Cefotaxime may decrease the excretion rate of Formestane which could result in a higher serum level.]
[B01AE03, argatroban, The therapeutic efficacy of Argatroban can be decreased when used in combination with Cefotaxime.]
[V03AB34, fomepizole, Cefotaxime may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[B01AC26, vorapaxar, The therapeutic efficacy of Vorapaxar can be decreased when used in combination with Cefotaxime.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Cefotaxime is combined with Acenocoumarol.]
[V08AA01, diatrizoic acid, Cefotaxime may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[V08AA04, iothalamic acid, Cefotaxime may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[S01AA15, dihydrostreptomycin, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Dihydrostreptomycin.]
[S03AA06, gentamicin, Cefotaxime may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Cefotaxime is combined with Dicoumarol.]
[B01AF03, edoxaban, Cefotaxime may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N02BE01, acetaminophen, Cefotaxime may decrease the excretion rate of Acetaminophen which could result in a higher serum level.]
[L01DC01, bleomycin, Cefotaxime may decrease the excretion rate of Bleomycin which could result in a higher serum level.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Cefotaxime is combined with Tioclomarol.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Adefovir dipivoxil.]
[A07DA06, eluxadoline, The excretion of Eluxadoline can be decreased when combined with Cefotaxime.]
[B01AC25, cangrelor, The therapeutic efficacy of Cangrelor can be decreased when used in combination with Cefotaxime.]
[M02AA25, aceclofenac, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Acemetacin.]
[S01EC01, acetazolamide, The therapeutic efficacy of Acetazolamide can be decreased when used in combination with Cefotaxime.]
[V03AB37, idarucizumab, Cefotaxime may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[J05AF13, tenofovir alafenamide, Cefotaxime may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01XG03, ixazomib, Cefotaxime may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[M04AB05, lesinurad, Cefotaxime may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[M01AE16, alminoprofen, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Alminoprofen.]
[N03AX23, brivaracetam, The therapeutic efficacy of Brivaracetam can be decreased when used in combination with Cefotaxime.]
[N05BA08, bromazepam, Cefotaxime may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[A02AD05, aluminum magnesium silicate, Cefotaxime may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[C03CA02, bumetanide, The excretion of Bumetanide can be decreased when combined with Cefotaxime.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Bupivacaine.]
[N05BE01, buspirone, Cefotaxime may decrease the excretion rate of Buspirone which could result in a higher serum level.]
[L01XX27, arsenic trioxide, Cefotaxime may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[M02AA03, clofezone, Cefotaxime may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[A07EC04, balsalazide, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Balsalazide.]
[A06AH05, naldemedine, Cefotaxime may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Cefotaxime may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Cefotaxime.]
[N03AX30, beclamide, The therapeutic efficacy of Beclamide can be decreased when used in combination with Cefotaxime.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Oxybuprocaine.]
[P01CA02, benznidazole, Cefotaxime may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J05AF06, abacavir, Cefotaxime may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[N07XX13, valbenazine, Cefotaxime may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[J01MA23, delafloxacin, Cefotaxime may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[B01AF04, betrixaban, The therapeutic efficacy of Betrixaban can be decreased when used in combination with Cefotaxime.]
[L01BC06, capecitabine, Cefotaxime may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[C07AB07, bisoprolol, Cefotaxime may decrease the excretion rate of Bisoprolol which could result in a higher serum level.]
[J01DC10, cefprozil, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefprozil.]
[R03BA02, budesonide, Cefotaxime may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[M01AB07, bumadizone, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Bumadizone.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Capsaicin.]
[R06AX18, acrivastine, Cefotaxime may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, The excretion of Captopril can be decreased when combined with Cefotaxime.]
[L02BB05, apalutamide, Cefotaxime may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, Cefotaxime may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[N03AX24, cannabidiol, The therapeutic efficacy of Cannabidiol can be decreased when used in combination with Cefotaxime.]
[L04AA37, baricitinib, The serum concentration of Baricitinib can be increased when it is combined with Cefotaxime.]
[J01DE01, cefepime, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefepime.]
[J01DD10, cefetamet, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefetamet.]
[J01DD09, cefodizime, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefodizime.]
[J01DC11, ceforanide, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Ceforanide.]
[J01DD13, cefpodoxime, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefpodoxime.]
[J01DD14, ceftibuten, The excretion of Ceftibuten can be decreased when combined with Cefotaxime.]
[J01GB14, plazomicin, Cefotaxime may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[A16AX14, migalastat, Cefotaxime may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The therapeutic efficacy of Stiripentol can be decreased when used in combination with Cefotaxime.]
[S01GX12, cetirizine, Cefotaxime may decrease the excretion rate of Cetirizine which could result in a higher serum level.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Cefotaxime may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Inotersen.]
[L01AD01, carmustine, Cefotaxime may decrease the excretion rate of Carmustine which could result in a higher serum level.]
[N07XX05, amifampridine, The risk or severity of seizure can be increased when Cefotaxime is combined with Amifampridine.]
[A06AX05, prucalopride, Cefotaxime may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[B01AC23, cilostazol, Cefotaxime may decrease the excretion rate of Cilostazol which could result in a higher serum level.]
[N06BA14, solriamfetol, Cefotaxime may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[N06AX29, brexanolone, The therapeutic efficacy of Brexanolone can be decreased when used in combination with Cefotaxime.]
[N05BA09, clobazam, The therapeutic efficacy of Clobazam can be decreased when used in combination with Cefotaxime.]
[J01DC04, cefaclor, The excretion of Cefaclor can be decreased when combined with Cefotaxime.]
[J01DB05, cefadroxil, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefadroxil.]
[J01DC03, cefamandole, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefamandole.]
[J01DB07, cefatrizine, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefatrizine.]
[J01DB04, cefazolin, The excretion of Cefazolin can be decreased when combined with Cefotaxime.]
[J01DC09, cefmetazole, The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Cefotaxime.]
[J01DC06, cefonicid, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefonicid.]
[J01DD12, cefoperazone, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefoperazone.]
[J01DC05, cefotetan, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefotetan.]
[J01DC07, cefotiam, The excretion of Cefotiam can be decreased when combined with Cefotaxime.]
[J01DC01, cefoxitin, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefoxitin.]
[J01DD03, cefsulodin, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefsulodin.]
[J01DD02, ceftazidime, The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefotaxime.]
[J01DD07, ceftizoxime, The excretion of Ceftizoxime can be decreased when combined with Cefotaxime.]
[J01DD04, ceftriaxone, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Ceftriaxone.]
[S01AA27, cefuroxime, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefuroxime.]
[N07XX11, pitolisant, Cefotaxime may decrease the excretion rate of Pitolisant which could result in a higher serum level.]
[J01XX09, daptomycin, Cefotaxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.]
[J01DB01, cephalexin, The excretion of Cephalexin can be decreased when combined with Cefotaxime.]
[J01DB02, cephaloridine, The excretion of Cefaloridine can be decreased when combined with Cefotaxime.]
[J01DB03, cephalothin, The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Cefotaxime.]
[J01DB08, cephapirin, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefapirin.]
[J01DB09, cephradine, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefradine.]
[N03AX25, cenobamate, The therapeutic efficacy of Cenobamate can be decreased when used in combination with Cefotaxime.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Givosiran.]
[M09AX08, golodirsen, Cefotaxime may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[S01XA12, dexpanthenol, Cefotaxime may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[R02AA03, dichlorobenzyl alcohol, Cefotaxime may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Cefotaxime may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[M01AH02, rofecoxib, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Rofecoxib.]
[C08CA16, clevidipine, Cefotaxime may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[N03AG02, dipropylacetamide, The therapeutic efficacy of Valpromide can be decreased when used in combination with Cefotaxime.]
[M01AC04, droxicam, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Droxicam.]
[V08CA05, mangafodipir, Cefotaxime may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[B01AE02, lepirudin, The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotaxime.]
[M02AA27, dexketoprofen, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The therapeutic efficacy of Clomethiazole can be decreased when used in combination with Cefotaxime.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Dyclonine.]
[P01BA01, chloroquine, Cefotaxime may decrease the excretion rate of Chloroquine which could result in a higher serum level.]
[N05AA01, chlorpromazine, Cefotaxime may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.]
[A10BB02, chlorpropamide, Cefotaxime may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.]
[M03BB03, chlorzoxazone, Cefotaxime may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.]
[N02BA07, ethenzamide, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Ethenzamide.]
[N06BX18, vinpocetine, The therapeutic efficacy of Vinpocetine can be decreased when used in combination with Cefotaxime.]
[M01AB08, etodolac, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Etofenamate.]
[M01AX25, chondroitin sulfates, Cefotaxime may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[N03AX10, felbamate, The therapeutic efficacy of Felbamate can be decreased when used in combination with Cefotaxime.]
[M01AE05, fenbufen, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Fenbufen.]
[C01CA19, fenoldopam, Cefotaxime may decrease the excretion rate of Fenoldopam which could result in a higher serum level.]
[J01DD15, cefdinir, The excretion of Cefdinir can be decreased when combined with Cefotaxime.]
[S02BA08, fluocinolone acetonide, Cefotaxime may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.]
[S01JA01, fluorescein, The excretion of Fluorescein can be decreased when combined with Cefotaxime.]
[N02BG07, flupirtine, Cefotaxime may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[A02BA01, cimetidine, The excretion of Cimetidine can be decreased when combined with Cefotaxime.]
[N02BF01, gabapentin, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Cefotaxime.]
[V08CA04, gadoteridol, Cefotaxime may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[S03AA07, ciprofloxacin, Cefotaxime may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L01XA01, cisplatin, Cefotaxime may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M01AG01, mefenamic acid, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Mefenamic acid.]
[B01AD11, tenecteplase, The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefotaxime.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Levobupivacaine.]
[N06AA04, clomipramine, Cefotaxime may decrease the excretion rate of Clomipramine which could result in a higher serum level.]
[N03AE01, clonazepam, The therapeutic efficacy of Clonazepam can be decreased when used in combination with Cefotaxime.]
[J05AH02, oseltamivir, The excretion of Oseltamivir can be decreased when combined with Cefotaxime.]
[N05AH02, clozapine, Cefotaxime may decrease the excretion rate of Clozapine which could result in a higher serum level.]
[J01GB12, arbekacin, Cefotaxime may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Cocaine.]
[M01AX13, proquazone, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Proquazone.]
[M04AC01, colchicine, Cefotaxime may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[J01XB01, colistin, Cefotaxime may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefpirome.]
[A04AA03, tropisetron, Cefotaxime may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[C04AX28, ifenprodil, The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Cefotaxime.]
[A10BX03, nateglinide, Cefotaxime may decrease the excretion rate of Nateglinide which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Imidazole salicylate.]
[B01AC10, indobufen, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Indobufen.]
[J05AB14, valganciclovir, Cefotaxime may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Cefotaxime may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Cefotaxime may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Cefotaxime may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Cefotaxime may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Cefotaxime may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Valdecoxib.]
[N02CC05, almotriptan, Cefotaxime may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[M01AH04, parecoxib, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Parecoxib.]
[B01AB12, bemiparin, The therapeutic efficacy of Bemiparin can be decreased when used in combination with Cefotaxime.]
[S01AD03, acyclovir, The excretion of Acyclovir can be decreased when combined with Cefotaxime.]
[N05BA10, ketazolam, Cefotaxime may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Kebuzone.]
[N03AX09, lamotrigine, The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Cefotaxime.]
[N07BC04, lofexidine, Cefotaxime may decrease the excretion rate of Lofexidine which could result in a higher serum level.]
[M01AB09, lonazolac, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Loxoprofen.]
[J01DC08, loracarbef, The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefotaxime.]
[C09AA03, lisinopril, Cefotaxime may decrease the excretion rate of Lisinopril which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Cefotaxime may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[J01DH02, meropenem, Cefotaxime may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[N05AD03, metylperon, Cefotaxime may decrease the excretion rate of Melperone which could result in a higher serum level.]
[J05AF07, tenofovir disoproxil, Cefotaxime may increase the nephrotoxic activities of Tenofovir disoproxil.]
[S01XA18, cyclosporine, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefotaxime.]
[C10AA07, rosuvastatin, The excretion of Rosuvastatin can be decreased when combined with Cefotaxime.]
[M02AA02, mofebutazone, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Morniflumate.]
[M01AH05, etoricoxib, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Etoricoxib.]
[L01AX04, dacarbazine, Cefotaxime may decrease the excretion rate of Dacarbazine which could result in a higher serum level.]
[M01AX01, nabumetone, The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Cefotaxime.]
[N07BB05, nalmefene, Cefotaxime may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[S01GX04, nedocromil, Cefotaxime may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, Cefotaxime may decrease the excretion rate of Nefazodone which could result in a higher serum level.]
[C01DX16, nicorandil, Cefotaxime may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Cefotaxime may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[N03AG06, tiagabine, The therapeutic efficacy of Tiagabine can be decreased when used in combination with Cefotaxime.]
[M03AC11, cisatracurium, Cefotaxime may increase the neuromuscular blocking activities of Cisatracurium.]
[B01AX05, fondaparinux, Cefotaxime may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[A07EC03, olsalazine, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Olsalazine.]
[N06AA01, desipramine, Cefotaxime may decrease the excretion rate of Desipramine which could result in a higher serum level.]
[H01BA02, desmopressin, Cefotaxime may decrease the excretion rate of Desmopressin which could result in a higher serum level.]
[V04CH02, indigo carmine, Cefotaxime may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Cefotaxime may decrease the excretion rate of Ertapenem which could result in a higher serum level.]
[M01AE12, oxaprozin, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The therapeutic efficacy of Oxcarbazepine can be decreased when used in combination with Cefotaxime.]
[S03BA01, dexamethasone, The excretion of Dexamethasone can be decreased when combined with Cefotaxime.]
[N06BA02, dextroamphetamine, Cefotaxime may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[N03AC01, paramethadione, The therapeutic efficacy of Paramethadione can be decreased when used in combination with Cefotaxime.]
[C01DA05, pentaerythritol tetranitrate, Cefotaxime may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[P03AC04, permethrin, Cefotaxime may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The therapeutic efficacy of Diazepam can be decreased when used in combination with Cefotaxime.]
[N03AX07, phenacemide, The therapeutic efficacy of Phenacemide can be decreased when used in combination with Cefotaxime.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Phenol.]
[N03AD02, phensuximide, The therapeutic efficacy of Phensuximide can be decreased when used in combination with Cefotaxime.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Cinchocaine.]
[R05DA08, pholcodine, Cefotaxime may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[M05BA02, clodronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotaxime is combined with Clodronic acid.]
[S01BC03, diclofenac, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Foscarnet.]
[A03AA07, dicyclomine, Cefotaxime may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF03, zalcitabine, The excretion of Zalcitabine can be decreased when combined with Cefotaxime.]
[J05AF02, didanosine, Cefotaxime may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[C08CA03, isradipine, Cefotaxime may decrease the excretion rate of Isradipine which could result in a higher serum level.]
[D07XC04, diflucortolone, Cefotaxime may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N02BA11, diflunisal, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Diflunisal.]
[C01AA05, digoxin, Cefotaxime may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02AA03, hydromorphone, Cefotaxime may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L04AX04, lenalidomide, Cefotaxime may decrease the excretion rate of Lenalidomide which could result in a higher serum level.]
[J05AE08, atazanavir, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Atazanavir.]
[H03BC01, potassium perchlorate, Cefotaxime may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Cefotaxime may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Pramocaine.]
[V03AB09, dimercaprol, Cefotaxime may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Cefotaxime may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N03AG05, progabide, The therapeutic efficacy of Progabide can be decreased when used in combination with Cefotaxime.]
[N02BB04, propyphenazone, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Proglumetacin.]
[G02AD02, dinoprostone, The excretion of Dinoprostone can be decreased when combined with Cefotaxime.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Diphenhydramine.]
[C09AA06, quinapril, The excretion of Quinapril can be decreased when combined with Cefotaxime.]
[B01AC07, dipyridamole, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefotaxime.]
[B01AD10, drotrecogin alfa, The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefotaxime.]
[S01AX06, resorcinol, Cefotaxime may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Cefotaxime may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[P03AA04, disulfiram, The risk or severity of adverse effects can be increased when Cefotaxime is combined with Disulfiram.]
[N07XX02, riluzole, The therapeutic efficacy of Riluzole can be decreased when used in combination with Cefotaxime.]
[R06AE09, levocetirizine, Cefotaxime may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Ropivacaine.]
[G04BE08, tadalafil, Cefotaxime may decrease the excretion rate of Tadalafil which could result in a higher serum level.]
[S01BC05, ketorolac, The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Cefotaxime.]
[C01EB18, ranolazine, Cefotaxime may decrease the excretion rate of Ranolazine which could result in a higher serum level.]
[N02BA06, salsalate, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Salsalate.]
[H05BA01, salmon calcitonin, Cefotaxime may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.]
[C01CA07, dobutamine, Cefotaxime may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[C01CA04, dopamine, Cefotaxime may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA12, doxepin, Cefotaxime may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01AA02, doxycycline, Cefotaxime may decrease the excretion rate of Doxycycline which could result in a higher serum level.]
[A08AA10, sibutramine, Cefotaxime may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[A12CA02, sodium sulfate, Cefotaxime may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Cefotaxime may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N02CC01, sumatriptan, Cefotaxime may decrease the excretion rate of Sumatriptan which could result in a higher serum level.]
[V04CX07, edrophonium, Cefotaxime may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[J01CG02, tazobactam, The excretion of Tazobactam can be decreased when combined with Cefotaxime.]
[L01AX03, temozolomide, Cefotaxime may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Cefotaxime.]
[M01AG02, tolfenamic acid, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Cefotaxime may decrease the excretion rate of Toloxatone which could result in a higher serum level.]
[N06BA09, atomoxetine, Cefotaxime may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[N03AX11, topiramate, The therapeutic efficacy of Topiramate can be decreased when used in combination with Cefotaxime.]
[N05CC01, chloral hydrate, Cefotaxime may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[B01AC18, triflusal, The therapeutic efficacy of Triflusal can be decreased when used in combination with Cefotaxime.]
[C05CA04, troxerutin, The therapeutic efficacy of Troxerutin can be decreased when used in combination with Cefotaxime.]
[N06AX16, venlafaxine, Cefotaxime may decrease the excretion rate of Venlafaxine which could result in a higher serum level.]
[M01AB04, zomepirac, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Zomepirac.]
[N03AX15, zonisamide, The therapeutic efficacy of Zonisamide can be decreased when used in combination with Cefotaxime.]
[B01AD03, anistreplase, The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefotaxime.]
[L01XA02, carboplatin, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Carboplatin.]
[C02AC02, guanfacine, Cefotaxime may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[L03AX05, pidotimod, Cefotaxime may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[N05CD04, estazolam, The therapeutic efficacy of Estazolam can be decreased when used in combination with Cefotaxime.]
[A02BC02, pantoprazole, Cefotaxime may decrease the excretion rate of Pantoprazole which could result in a higher serum level.]
[G03CA03, estradiol, The excretion of Estradiol can be decreased when combined with Cefotaxime.]
[G03CA57, estrogens, conjugated (USP), The excretion of Conjugated estrogens can be decreased when combined with Cefotaxime.]
[J04AK02, ethambutol, Cefotaxime may decrease the excretion rate of Ethambutol which could result in a higher serum level.]
[V08CA03, gadodiamide, Cefotaxime may decrease the excretion rate of Gadodiamide which could result in a higher serum level.]
[C01BD05, ibutilide, Cefotaxime may decrease the excretion rate of Ibutilide which could result in a higher serum level.]
[N03AD01, ethosuximide, The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Cefotaxime.]
[N03AB01, ethotoin, The therapeutic efficacy of Ethotoin can be decreased when used in combination with Cefotaxime.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Etidocaine.]
[N01AX07, etomidate, Cefotaxime may decrease the excretion rate of Etomidate which could result in a higher serum level.]
[L04AD02, tacrolimus, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Tacrolimus.]
[P01AX07, trimetrexate, Cefotaxime may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The risk or severity of seizure can be increased when Bupropion is combined with Cefotaxime.]
[N06AB08, fluvoxamine, Cefotaxime may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.]
[L02AE02, leuprolide, Cefotaxime may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[C10AA03, pravastatin, The excretion of Pravastatin can be decreased when combined with Cefotaxime.]
[M01CB01, gold sodium thiomalate, Cefotaxime may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Cefotaxime may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Cefotaxime may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.]
[A02BA03, famotidine, The excretion of Famotidine can be decreased when combined with Cefotaxime.]
[A16AA01, levocarnitine, The excretion of Levocarnitine can be decreased when combined with Cefotaxime.]
[N03AX26, fenfluramine, The therapeutic efficacy of Fenfluramine can be decreased when used in combination with Cefotaxime.]
[M01AE04, fenoprofen, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Fenoprofen.]
[N02AB03, fentanyl, Cefotaxime may decrease the excretion rate of Fentanyl which could result in a higher serum level.]
[R03CC02, albuterol, Cefotaxime may decrease the excretion rate of Salbutamol which could result in a higher serum level.]
[B01AD05, plasmin, The therapeutic efficacy of Fibrinolysin can be decreased when used in combination with Cefotaxime.]
[L01BB06, clofarabine, The excretion of Clofarabine can be decreased when combined with Cefotaxime.]
[N07AX03, cevimeline, Cefotaxime may decrease the excretion rate of Cevimeline which could result in a higher serum level.]
[G04BD02, flavoxate, Cefotaxime may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[N02BG04, floctafenine, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Floctafenine.]
[J02AC01, fluconazole, Cefotaxime may decrease the excretion rate of Fluconazole which could result in a higher serum level.]
[J02AX01, flucytosine, Cefotaxime may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Cefotaxime may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N07CA03, flunarizine, The therapeutic efficacy of Flunarizine can be decreased when used in combination with Cefotaxime.]
[L01BC09, floxuridine, Cefotaxime may decrease the excretion rate of Floxuridine which could result in a higher serum level.]
[N05CD01, flurazepam, Cefotaxime may decrease the excretion rate of Flurazepam which could result in a higher serum level.]
[S01BC04, flurbiprofen, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Flurbiprofen.]
[L02BB01, flutamide, Cefotaxime may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Cefotaxime may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[S02AA17, fosfomycin, Cefotaxime may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Cefotaxime.]
[L01BC03, tegafur, Cefotaxime may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[C03CA01, furosemide, Furosemide may decrease the excretion rate of Cefotaxime which could result in a higher serum level.]
[M05BA04, alendronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotaxime is combined with Alendronic acid.]
[N05CF04, eszopiclone, Cefotaxime may decrease the excretion rate of Eszopiclone which could result in a higher serum level.]
[S01AD09, ganciclovir, Cefotaxime may decrease the excretion rate of Ganciclovir which could result in a higher serum level.]
[N03AA04, barbexaclone, The therapeutic efficacy of Barbexaclone can be decreased when used in combination with Cefotaxime.]
[C10AB04, gemfibrozil, Cefotaxime may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, Cefotaxime may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[N03AD03, methsuximide, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Cefotaxime.]
[A10BB07, glipizide, Cefotaxime may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, Cefotaxime may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.]
[L01EX02, sorafenib, Cefotaxime may decrease the excretion rate of Sorafenib which could result in a higher serum level.]
[M01CB04, aurothioglucose, Cefotaxime may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Cefotaxime may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Cefotaxime is combined with Fluindione.]
[C09AA09, fosinopril, Cefotaxime may decrease the excretion rate of Fosinopril which could result in a higher serum level.]
[S01EX01, guanethidine, Cefotaxime may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, Cefotaxime may decrease the excretion rate of Goserelin which could result in a higher serum level.]
[N05AD01, haloperidol, Cefotaxime may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[N05AH04, quetiapine, Cefotaxime may decrease the excretion rate of Quetiapine which could result in a higher serum level.]
[N06BX13, idebenone, Cefotaxime may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[M04AA01, allopurinol, The excretion of Allopurinol can be decreased when combined with Cefotaxime.]
[S01XA14, heparin, The therapeutic efficacy of Heparin can be decreased when used in combination with Cefotaxime.]
[G03DC01, allylestrenol, Cefotaxime may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefotaxime.]
[C01CE02, milrinone, Cefotaxime may decrease the excretion rate of Milrinone which could result in a higher serum level.]
[N05CA16, hexobarbital, The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Cefotaxime.]
[M02AA26, nimesulide, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Nimesulide.]
[C09AA04, perindopril, Cefotaxime may decrease the excretion rate of Perindopril which could result in a higher serum level.]
[C02DB02, hydralazine, Cefotaxime may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, The excretion of Hydrochlorothiazide can be decreased when combined with Cefotaxime.]
[S02BA01, hydrocortisone, The excretion of Hydrocortisone can be decreased when combined with Cefotaxime.]
[B05XA17, potassium acetate, Cefotaxime may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[V03AB33, hydroxocobalamin, Cefotaxime may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.]
[G04BD06, propiverine, Cefotaxime may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[B05AA07, hetastarch, Cefotaxime may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[M05BA07, risedronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotaxime is combined with Risedronic acid.]
[R02AX02, ibuprofen, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Ibuprofen.]
[B05XA08, sodium acetate, Cefotaxime may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefotaxime.]
[L01AA06, ifosfamide, Cefotaxime may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N06AA02, imipramine, Cefotaxime may decrease the excretion rate of Imipramine which could result in a higher serum level.]
[R01AD07, tixocortol, Cefotaxime may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Cefotaxime.]
[L01CE01, topotecan, Cefotaxime may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, Cefotaxime may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[S01BC01, indomethacin, The excretion of Indomethacin can be decreased when combined with Cefotaxime.]
[A11HA07, inositol, Cefotaxime may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, Cefotaxime may decrease the excretion rate of Milnacipran which could result in a higher serum level.]
[S01XA28, varenicline, Cefotaxime may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Articaine.]
[A10BH01, sitagliptin, The excretion of Sitagliptin can be decreased when combined with Cefotaxime.]
[N05BA12, alprazolam, Cefotaxime may decrease the excretion rate of Alprazolam which could result in a higher serum level.]
[N05CH02, ramelteon, Cefotaxime may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[V03AB01, ipecac, Cefotaxime may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[J05AF04, stavudine, The excretion of Stavudine can be decreased when combined with Cefotaxime.]
[G04BE01, alprostadil, The excretion of Alprostadil can be decreased when combined with Cefotaxime.]
[J04AC01, isoniazid, Cefotaxime may decrease the excretion rate of Isoniazid which could result in a higher serum level.]
[J05AX05, inosine pranobex, Cefotaxime may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[C01DA14, isosorbide mononitrate, Cefotaxime may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10BA01, isotretinoin, Cefotaxime may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[B01AE06, bivalirudin, The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefotaxime.]
[S01AA24, kanamycin, Cefotaxime may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[N01AX03, ketamine, Cefotaxime may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[B01AC22, prasugrel, Cefotaxime may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[M02AA10, ketoprofen, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Ketoprofen.]
[M01AE11, tiaprofenic acid, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Tiaprofenic acid.]
[C07AG01, labetalol, Cefotaxime may decrease the excretion rate of Labetalol which could result in a higher serum level.]
[N04BB01, amantadine, Cefotaxime may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A06AX03, lubiprostone, Cefotaxime may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Cefotaxime.]
[C03CC01, ethacrynic acid, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Etacrynic acid.]
[S01AA21, amikacin, Cefotaxime may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N05BA06, lorazepam, The therapeutic efficacy of Lorazepam can be decreased when used in combination with Cefotaxime.]
[B05XA11, magnesium chloride, Cefotaxime may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Cefotaxime may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Cefotaxime.]
[L01BA05, pralatrexate, Cefotaxime may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefotaxime.]
[N06AA21, maprotiline, Cefotaxime may decrease the excretion rate of Maprotiline which could result in a higher serum level.]
[C02BB01, mecamylamine, Cefotaxime may decrease the excretion rate of Mecamylamine which could result in a higher serum level.]
[M02AA18, meclofenamic acid, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Meclofenamic acid.]
[N05BA03, medazepam, The therapeutic efficacy of Medazepam can be decreased when used in combination with Cefotaxime.]
[B01AB06, nadroparin, The therapeutic efficacy of Nadroparin can be decreased when used in combination with Cefotaxime.]
[B01AB05, enoxaparin, The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Cefotaxime.]
[B01AB04, dalteparin, The therapeutic efficacy of Dalteparin can be decreased when used in combination with Cefotaxime.]
[N06DX01, memantine, Cefotaxime may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, Cefotaxime may decrease the excretion rate of Meperidine which could result in a higher serum level.]
[N03AB04, mephenytoin, The therapeutic efficacy of Mephenytoin can be decreased when used in combination with Cefotaxime.]
[N03AA01, mephobarbital, The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Cefotaxime.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Mepivacaine.]
[G04BX16, tiopronin, Cefotaxime may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Cefotaxime may decrease the excretion rate of Mersalyl which could result in a higher serum level.]
[N05AX13, paliperidone, Cefotaxime may decrease the excretion rate of Paliperidone which could result in a higher serum level.]
[A10BA02, metformin, Cefotaxime may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N07BC02, methadone, Cefotaxime may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N06BA03, methamphetamine, Cefotaxime may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[J05AF05, lamivudine, Cefotaxime may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[N03AA30, metharbital, The therapeutic efficacy of Metharbital can be decreased when used in combination with Cefotaxime.]
[H03BB02, methimazole, Cefotaxime may decrease the excretion rate of Methimazole which could result in a higher serum level.]
[L01BA04, pemetrexed, Cefotaxime may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[N05CA15, methohexital, The therapeutic efficacy of Methohexital can be decreased when used in combination with Cefotaxime.]
[A11HA02, pyridoxine, Cefotaxime may decrease the excretion rate of Pyridoxine which could result in a higher serum level.]
[L04AX03, methotrexate, The excretion of Methotrexate can be decreased when combined with Cefotaxime.]
[D05BA02, methoxsalen, Cefotaxime may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[C02AB01, methyldopa, Cefotaxime may decrease the excretion rate of Methyldopa which could result in a higher serum level.]
[V04CG05, methylene blue, Cefotaxime may decrease the excretion rate of Methylene blue which could result in a higher serum level.]
[N03AF03, rufinamide, The therapeutic efficacy of Rufinamide can be decreased when used in combination with Cefotaxime.]
[G03EK01, methyltestosterone, Cefotaxime may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[A03FA01, metoclopramide, Cefotaxime may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C03BA08, metolazone, Cefotaxime may decrease the excretion rate of Metolazone which could result in a higher serum level.]
[C07AB02, metoprolol, Cefotaxime may decrease the excretion rate of Metoprolol which could result in a higher serum level.]
[V04CD01, metyrapone, Cefotaxime may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[N02BB03, aminopyrine, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Aminophenazone.]
[B01AB07, parnaparin, The therapeutic efficacy of Parnaparin can be decreased when used in combination with Cefotaxime.]
[N05CD08, midazolam, Cefotaxime may decrease the excretion rate of Midazolam which could result in a higher serum level.]
[B01AB10, tinzaparin, The therapeutic efficacy of Tinzaparin can be decreased when used in combination with Cefotaxime.]
[J05AH01, zanamivir, Cefotaxime may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[L03AC01, aldesleukin, Cefotaxime may decrease the excretion rate of Aldesleukin which could result in a higher serum level.]
[N06AA09, amitriptyline, Cefotaxime may decrease the excretion rate of Amitriptyline which could result in a higher serum level.]
[A04AA05, palonosetron, Cefotaxime may decrease the excretion rate of Palonosetron which could result in a higher serum level.]
[J01DD06, moxalactam, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Latamoxef.]
[L04AB05, certolizumab pegol, Cefotaxime may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[G04BA01, ammonium chloride, Cefotaxime may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L04AA06, mycophenolic acid, Cefotaxime may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[N05CA02, amobarbital, The therapeutic efficacy of Amobarbital can be decreased when used in combination with Cefotaxime.]
[N03AB05, fosphenytoin, The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Cefotaxime.]
[C07AA12, nadolol, Cefotaxime may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01CA04, amoxicillin, Cefotaxime may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[V03AB15, naloxone, Cefotaxime may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[N06BA01, amphetamine, Cefotaxime may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[M02AA12, naproxen, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Naproxen.]
[N06AX21, duloxetine, Cefotaxime may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N04BX01, tolcapone, Cefotaxime may decrease the excretion rate of Tolcapone which could result in a higher serum level.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Neomycin.]
[B01AC17, tirofiban, Cefotaxime may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[J02AA01, amphotericin B, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Amphotericin B.]
[S01AA19, ampicillin, Cefotaxime may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Cefotaxime may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Cefotaxime may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, Cefotaxime may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.]
[J05AB11, valacyclovir, The excretion of Valaciclovir can be decreased when combined with Cefotaxime.]
[C01CE01, inamrinone, Cefotaxime may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C08CA05, nifedipine, Cefotaxime may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Niflumic acid.]
[C08CA07, nisoldipine, Cefotaxime may decrease the excretion rate of Nisoldipine which could result in a higher serum level.]
[N05CD02, nitrazepam, The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Cefotaxime.]
[R07AX01, nitric oxide, Cefotaxime may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Cefotaxime may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Cefotaxime.]
[N04BC05, pramipexole, Cefotaxime may decrease the excretion rate of Pramipexole which could result in a higher serum level.]
[C02DD01, nitroprusside, Cefotaxime may decrease the excretion rate of Nitroprusside which could result in a higher serum level.]
[B01AB08, reviparin, The therapeutic efficacy of Reviparin can be decreased when used in combination with Cefotaxime.]
[N02AA02, opium, Cefotaxime may decrease the excretion rate of Opium which could result in a higher serum level.]
[B01AD07, reteplase, The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefotaxime.]
[B01AD09, ancrod, The therapeutic efficacy of Ancrod can be decreased when used in combination with Cefotaxime.]
[G04CA02, tamsulosin, Cefotaxime may decrease the excretion rate of Tamsulosin which could result in a higher serum level.]
[M05BA08, zoledronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotaxime is combined with Zoledronic acid.]
[J01CF04, oxacillin, Cefotaxime may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[N05BA04, oxazepam, Cefotaxime may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[S01BC02, oxyphenbutazone, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Oxyphenbutazone.]
[S01AA04, oxytetracycline, The excretion of Oxytetracycline can be decreased when combined with Cefotaxime.]
[V04CH30, 4-aminohippuric acid, The excretion of Aminohippuric acid can be decreased when combined with Cefotaxime.]
[B01AB09, danaparoid, The therapeutic efficacy of Danaparoid can be decreased when used in combination with Cefotaxime.]
[J04AB30, capreomycin, Cefotaxime may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[N05CC05, paraldehyde, The therapeutic efficacy of Paraldehyde can be decreased when used in combination with Cefotaxime.]
[A07AA06, paromomycin, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Paromomycin.]
[G04BD11, fesoterodine, Cefotaxime may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, Cefotaxime may decrease the excretion rate of Penbutolol which could result in a higher serum level.]
[S01AA14, penicillin G, The excretion of Benzylpenicillin can be decreased when combined with Cefotaxime.]
[J01CE09, penicillin G procaine, Cefotaxime may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Cefotaxime.]
[L01XX08, pentostatin, Cefotaxime may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Cefotaxime may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Phenazopyridine.]
[N06AF03, phenelzine, Cefotaxime may decrease the excretion rate of Phenelzine which could result in a higher serum level.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Cefotaxime is combined with Phenindione.]
[N03AA02, phenobarbital, The therapeutic efficacy of Phenobarbital can be decreased when used in combination with Cefotaxime.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Cefotaxime is combined with Phenprocoumon.]
[V03AB36, phentolamine, Cefotaxime may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Phenylbutazone.]
[N03AB02, phenytoin, The therapeutic efficacy of Phenytoin can be decreased when used in combination with Cefotaxime.]
[S01AE05, levofloxacin, Cefotaxime may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N07BB03, acamprosate, The excretion of Acamprosate can be decreased when combined with Cefotaxime.]
[B02BA01, vitamin K1, Cefotaxime may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefotaxime.]
[C07AA03, pindolol, Cefotaxime may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01CA12, piperacillin, The excretion of Piperacillin can be decreased when combined with Cefotaxime.]
[N06BX03, piracetam, Cefotaxime may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[S01BC06, piroxicam, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Piroxicam.]
[J01DD16, cefditoren, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefditoren.]
[J01MA11, grepafloxacin, The excretion of Grepafloxacin can be decreased when combined with Cefotaxime.]
[B01AC13, abciximab, The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefotaxime.]
[S01XA13, alteplase, The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefotaxime.]
[A10BG02, rosiglitazone, Cefotaxime may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[S03AA03, polymyxin B, The risk or severity of adverse effects can be increased when Cefotaxime is combined with Polymyxin B.]
[C03AA05, polythiazide, The excretion of Polythiazide can be decreased when combined with Cefotaxime.]
[A10BH03, saxagliptin, The excretion of Saxagliptin can be decreased when combined with Cefotaxime.]
[B05XA01, potassium chloride, Cefotaxime may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[H02AB07, prednisone, Cefotaxime may decrease the excretion rate of Prednisone which could result in a higher serum level.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Prilocaine.]
[N03AA03, primidone, The therapeutic efficacy of Primidone can be decreased when used in combination with Cefotaxime.]
[M04AB01, probenecid, The serum concentration of Cefotaxime can be increased when it is combined with Probenecid.]
[C01BA02, procainamide, Cefotaxime may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Procaine.]
[C10AB05, fenofibrate, Cefotaxime may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[R06AD02, promethazine, Cefotaxime may decrease the excretion rate of Promethazine which could result in a higher serum level.]
[A03AB05, propantheline, Cefotaxime may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[R06AX26, fexofenadine, The excretion of Fexofenadine can be decreased when combined with Cefotaxime.]
[C07AA05, propranolol, Cefotaxime may decrease the excretion rate of Propranolol which could result in a higher serum level.]
[N02CC04, rizatriptan, Cefotaxime may decrease the excretion rate of Rizatriptan which could result in a higher serum level.]
[B01AC09, epoprostenol, Cefotaxime may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N07XX07, dalfampridine, The risk or severity of seizure can be increased when Cefotaxime is combined with Dalfampridine.]
[P02CC01, pyrantel, Cefotaxime may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Cefotaxime may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[C01BA01, quinidine, Cefotaxime may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[A02BA02, ranitidine, The excretion of Ranitidine can be decreased when combined with Cefotaxime.]
[C02AA02, reserpine, Cefotaxime may decrease the excretion rate of Reserpine which could result in a higher serum level.]
[J05AP01, ribavirin, Cefotaxime may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[N02BA05, salicylamide, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Salicylic acid.]
[N05CA06, secobarbital, The therapeutic efficacy of Secobarbital can be decreased when used in combination with Cefotaxime.]
[J01GB08, sisomicin, Cefotaxime may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Cefotaxime may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Cefotaxime may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[N02BA03, choline salicylate, Cefotaxime may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[V09AB03, ioflupane I-123, Cefotaxime may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Cefotaxime may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Cefotaxime may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[N03AG01, valproic acid, The excretion of Valproic acid can be decreased when combined with Cefotaxime.]
[M05BA01, etidronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotaxime is combined with Etidronic acid.]
[D10AX03, azelaic acid, Cefotaxime may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
